India, July 1 -- Genenta Science S.p.A. (GNTA), Tuesday announced long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme patients.
The study enrolled a total of 38 patients, with 25 patients receiving Temferon. Of this, two patients survived three years from the time of the first surgery.
The company noted that a 29 percent two-year survival rate for unmethylated MGMT patients, with median overall survival at 17 months. This is in comparison to patients receiving standard of care have shown a two-year survival rate of approximately 14 percent and a median overall survival of 13 to 15 months.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Also, the company has initiate...